The information contained in company statements should be considered accurate only as of the date of the company statement. We disclaim any obligation to supplement or update the information in these company statements.
2024 Incyte Ingenuity Awards in GVHD™ Awarded to Memorial Sloan Kettering Cancer Center and Thomas Jefferson University
November 1, 2024
Incyte Expands its Support for People Living with Vitiligo Launching Vitiligo Innovators Program™ in Conjunction with Incyte Ingenuity Awards in Vitiligo™
June 22, 2024
2023 Incyte Ingenuity Awards in Graft-Versus-Host Disease Awarded to Vanderbilt University and Massachusetts General Hospital Institute of Health Professions
November 1, 2023
Incyte Announces Inaugural Incyte Ingenuity Award Program Recipients, Recognizing Innovative Solutions for the Vitiligo Community
June 25, 2023
Cincinnati Children’s Hospital Medical Center and Children’s Healthcare of Atlanta Receive 2022 Incyte Ingenuity Awards in Graft-Versus-Host Disease
November 1, 2022
Incyte Recognized as an Exceptional Workplace by both Science Magazine and Newsweek
October 27, 2022
Incyte Pledges Support to Vitiligo Community through Expansion of Ingenuity Award Program
June 25, 2022
Incyte Announces European Commission Approval of Tabrecta® (capmatinib) for METex14 Skipping Advanced Non-Small Cell Lung Cancer
June 22, 2022
Incyte Reaffirms Commitment to Delaware Community by Opening New Research Facility and Extending the Incyte Cancer Care Assistance Fund for Delaware
April 4, 2022
Corporate Statement Regarding Opzelura™ (ruxolitinib) Cream
November 2, 2021
Incyte Announces 2021 Incyte Ingenuity Award Program Recipients, Recognizing Innovative Solutions for the GVHD Community
October 29, 2021
Incyte Ranked Second Among Science Magazine’s 2021 Top Biopharma Employers
October 28, 2021
Incyte Named to Newsweek’s List of America’s Most Loved Workplaces for 2021
October 22, 2021
Incyte Announces Progress on Global Responsibility Initiatives and Sets Corporate Goals for the Next Four Years
July 28, 2021
Incyte Statement Regarding U.S. Department of Justice Settlement
May 4, 2021
Annual Call for Submissions Open for the Incyte Ingenuity Award Program
February 24, 2021
Incyte Joins the Myeloproliferative Neoplasm (MPN) Community in Recognizing MPN Awareness Day and the 10th Anniversary of Blood Cancer Awareness Month
September 1, 2020
Data from Investigator Initiated Study of Ruxolitinib in Patients with Severe COVID-19 Published in the Journal of Allergy and Clinical Immunology
May 26, 2020
Incyte Provides Statement on NIH Initiated Trial of Baricitinib in Combination with Remdesivir for Patients with COVID-19
May 8, 2020
Incyte Provides Updated Statement on Response to COVID-19
March 30, 2020
Incyte Named a Top Five Biopharma Employer by Science Magazine
October 24, 2019
Incyte Supports Wilmington Friends School Strategic Vision and Plan for the Future
October 10, 2019
Incyte Provides Statement on World Health Organization Global Medical Product Alert for Iclusig® (ponatinib)
May 3, 2019
Incyte Provides Statement on Incyte Corporation versus Flexus Biosciences, Inc. Verdict
November 8, 2018
